CASE Op-Ed in DC Journal: Talc Litigation Plan Will Finally End Plaintiffs Suffering, Debunk Faulty Science
For 15 years and counting, the Johnson & Johnson talc litigation saga continues to play out in our nation’s court system, adding...
CASE Op-Ed in American Spectator: Time to Curb Lawyers’ Late-Night TV Ads
he problem with our legal system, comedian Steven Wright points out, is that “99 percent of lawyers give the...
CASE OP-Ed in DC Journal: Mass Tort Litigation Makes Us All Poorer
February 13, 2024 As regular viewers of late-night television know, commercial breaks are filled with endless ads recruiting potential...
CASE Op-Ed in Townhall: A Renewed Focus on Legal Reform Offers a Quick Path to Economic Stimulus
October 25, 2023 People can get a good chuckle reading the latest legal news, offering up cases such as...
CASE Reaffirms Opposition to Federal Tort Reform Bill
This week CASE reaffirmed it’s opposition to H.R. 1215, the deceptively titled “Protecting Access to Care Act of 2017,” which seeks to...
Update: House Pulls Tort Reform Bill that Tramples Principles of Constitution
Congressional Tort Reform Legislation Tramples Principles of Constitution Update: CASE reported earlier this month that the GOP-led House was considering a...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/